Anthony Stack, DO (@TonyCStack) header
Anthony Stack, DO (@TonyCStack) profile picture

Hematologist/Oncologist | Lymphoma, BMT and Cellular Therapy | Fox Chase Cancer Center Views are my own

Philadelphia, PA
Joined November 2017
Photo by Anthony Stack, DO (@TonyCStack)Photo by Anthony Stack, DO (@TonyCStack)Photo by Anthony Stack, DO (@TonyCStack)Photo by Anthony Stack, DO (@TonyCStack)
Pick any medical specialty other than your own. Who’s the most famous physician in it? You probably can’t name one. Almost none of us will be known outside our field, and even those who achieve real professional fame are mostly forgotten within a few decades. Fame is a poor reason to devote your life to medicine. The work itself matters more: caring for patients, discovering new knowledge, and teaching the next generation.
58
280
47
1,138
127,863
A persistent, itchy rash that doesn't improve with treatment could be more than eczema or psoriasis. Anthony Stack, MD, of Fox Chase Cancer Center explains the signs of cutaneous lymphoma, a rare cancer that often goes undiagnosed for years: bit.ly/4vPApfO
1
3
366
Anthony Stack, DO retweeted
#ASCO26 #AML #leusm Does venetoclax duration matter in frontline HMA+Ven for AML? Poster: In a @MayoCancerCare analysis of 540 newly diagnosed AML patients, outcomes were driven primarily by disease biology, not venetoclax duration. Led by Dr. Naseema Gangat 👏👏👏 🔹 Similar OS across 7-, 14-, 21-, and 28-day schedules 🔹 Comparable outcomes within ELN 2024 and Mayo genetic risk groups 🔹 Higher early mortality with shorter durations likely reflected selection of frailer patients 🔹 In ELN high-risk AML, 14-day venetoclax was associated with inferior survival compared with 21- and 28-day schedules Take-home: Venetoclax duration should be individualized based on genetics, response, cytopenias, and patient fitness rather than a one-size-fits-all approach.
27
1
65
3,363
Anthony Stack, DO retweeted
Scarisbrick et al - PROCLIPI - prospec CTCL registry, 549 adv stage - 5y OS 50%, IIIA better - Prog factors: Age >60, N3, LDH incr, large cell Tx in skin - Assoc with OS, PFS - HRQoL also assoc v useful as current staging system difficult & does not prognosticate #ASH2025 #lymsm
1
6
20
1,444
Anthony Stack, DO retweeted
Original Article: Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (MajesTEC-3 phase 3 trial) nej.md/4431DUD #ASH25 | @ASH_hematology
1
31
6
109
24,685
Anthony Stack, DO retweeted
Chapuy et al - R-Pola-Glo in unfit / frail 1L DLBCL - PhII, 80 pts, not eligible full dose R-CHOP - by sGA, 91% 'unfit / frail', med age 80y - ICANS 4%, NRM 4% - 22% G3/4 infectn - 1y PFS 85% (15mo FU) - CMR 81% cycle 12 Very impressive and looks well tolerated. #ASH2025 #lymsm
26
1
62
5,516
This prospective international analysis demonstrated a real-world t(11;14) detection rate of 22.1% in patients with MM. Read in Blood Advances: ow.ly/25aM50XyeiT #MultipleMyeloma #BloodAdvances
3
24
3,020
Guidelines for T cell nomenclature bit.ly/48258LX
67
5
193
22,503
Anthony Stack, DO retweeted
Treatment algorithm for frontline Ph-positive B- cell ALL onlinelibrary.wiley.com/doi/… #leusm #ALL
15
1
68
3,717
Anthony Stack, DO retweeted
✨ IgG4-Related Disease: Emerging Insights One of the best #IgG4RD articles I’ve come across! Published in Allergy (2025) 🧾 🔹 4 Clinical Phenotypes Pancreato-biliary | Retroperitoneal/Aortitis | Head & Neck | Mikulicz/Systemic 🔹 Key Biomarkers Plasmablasts, galectin-3, CCL18 🔬 Serum IgG4 → supportive, not specific 🚫 🔹 Genetics & Pathogenesis HLA-DRB1, FCGR2B, IKZF1 variants 🧬 CD4⁺ CTLs, Tfh2/BATF⁺ Tfh, ILC2s, M2 macrophages → fibrosis & immune dysregulation Microbiome: ↑Streptococcus/Clostridium, ↓butyrate producers 🔹 Therapeutics Steroids = fast, but relapse 40% ⚠️ Rituximab = effective 💉 Inebilizumab (FDA 2025) → 87% flare reduction 🚀 Pipeline: BTK, JAKi, dupilumab, daratumumab 🔹 Future Directions Multi-omics, novel biomarkers, fibrosis pathways (IL-33/ST2, IL-6/IL-6R) ➡️ Towards precision, steroid-sparing therapy 👉 IgG4-RD = fibrosis + immune dysregulation + B/T cell crosstalk Truly a landmark review shaping tomorrow’s #PrecisionMedicine ✨ DOI: 10.1111/all.16686 #IgG4RD #Allergy #Immunology #Rheumatology #Fibrosis
6
115
2
312
22,916
Anthony Stack, DO retweeted
Just out in the New England Journal of Medicine! Our comprehensive Review on MGUS: Monoclonal Gammopathy of Undetermined Significance @NEJM nejm.org/doi/full/10.1056/NE… 5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and Figures. Bookmark! How to test and manage patients. Who needs bone marrow exams and scans. It’s all in here! MGUS is important not just because it’s a precursor to multiple myeloma. It causes a lot of other problems. Learn all about MGUS, and the various terms you hear MGCS, MGRS etc. in this Review @myelomaMD and I have tried to keep every sentence in this Review simple and easy to follow. #MGUSVR
26
292
20
972
121,662
Anthony Stack, DO retweeted
Looks like we need 50-year mortgages.
23
59
4
378
88,101
Anthony Stack, DO retweeted
Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma ashpublications.org/blood/ar…
4
24
1,467
Anthony Stack, DO retweeted
The tumultuous development of venetoclax in t(11;14) multiple myeloma Just out in @JCO_ASCO Preview below 👇🏻 ascopubs.org/doi/10.1200/JCO… @MyMKaiser @OncoAlert
1
15
1
48
6,700
1/ New @BloodAdvances treasure trove of 🇩🇪 🇺🇸 data about bridging before CAR-T in #MMsm. Bigger is not better when it comes to bridging using chemotherapy... Worse post-CAR-T efficacy (unsurprising: tumor biology as confounder) but also clearly worse cytopenias & infections!
4
10
2
51
8,120
How I treat acute lymphoblastic leukemia in the era of immunotherapy while revisiting the myth of second remission ow.ly/VNYF50WBFRq #HowITreat #lymphoidneoplasia #transplantation
20
69
4,867
1/ As @End_myeloma has said so eloquently: "The only place where BCMA must come before GPRC5D is the dictionary." Talquetamab bridging before BCMA CAR-T in myeloma - short, very effective, and rapidly becoming my preferred approach for patients with aggressive #MMsm biology!
🎉Finally out🎉 Talquetamab bridging is feasible, safe and effective allowing rapid disease control with minimal grade toxicity @BloodPortfolio ashpublications.org/blood/ar… #mmsm
1
22
1
77
9,378
🧵 How I treat platelet transfusion refractoriness 🩸 Blood 2025 review by Nahirniak et al. 1️⃣ Definition: PR = inadequate post-transfusion platelet increment (PI ≤ 5–10×10⁹/L) on 2 occasions. 📊 CCI = (PI × BSA) / platelet dose. 2️⃣ Causes: 🔹 Immune (HLA antibodies – class I mostly) 🔹 Non-immune (infection, fever, splenomegaly, DIC, meds) 3️⃣ Diagnosis: 🧪 Luminex > Flow cytometry > LCT 🧬 Strong MFI >5000 or cumulative DSA-MFI ≥10,000 → PR likely. 4️⃣ Immune PR: 🧬 HLA alloimmunization in ~80–90% of immune PR. 👩‍🍼 Multiparous women at risk. 💉 Desensitization: PLEX + IVIG + Rituximab ± Bortezomib. 5️⃣ Platelet Options: 🧬 HLA-matched ✅ Crossmatch-compatible 🔬 HLA-selected (antigen-negative for DSA) 🧠 Emerging: Epitope-matched via HLAMatchmaker 6️⃣ Non-immune PR: ⚠️ No benefit from HLA-matched platelets. 🩹 Focus on treating underlying cause. 🚫 Avoid routine transfusions in non-bleeding patients. 7️⃣ Adjuncts: 🦷 Tranexamic acid (safe but doesn’t reduce bleeding or mortality) 💧 Continuous platelet infusion (case reports only) 8️⃣ Algorithm available 🧭 Check MFI + PI + bleeding + rule out non-immune causes → tailor therapy accordingly. 📚 Credits: Dr. Abdulrahman Nasiri for sharing 📖 Nahirniak S, Nadarajan V, Stanworth SJ. Blood. 2025;145(20):2293-2300. 🔗 doi.org/10.1182/blood.202302… #PlateletRefractoriness #Transfusion #Hematology #HLA #Alloimmunization #Blood2025
12
37
1,499
Anthony Stack, DO retweeted
Early methionine availability attenuates T cell exhaustion @NatImmunol nature.com/articles/s41590-0…
18
1
79
5,088